Effect of Intake of Dehydrated Nopal Powder From Highly Mature Cladodes on the Lipid Profile
NCT ID: NCT07018908
Last Updated: 2025-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2018-06-01
2019-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Nopales (Opuntia Spp.) on Lipoprotein Profile and Oxidative Stress in Moderately Hypercholesterolemic Adults
NCT02209493
Safety and Efficacy Study of Herbal Supplements in Prediabetic and Mild to Moderate Hyperlipidemic Patients
NCT01680211
Efficacy and Safety of Platycodon Grandiflorus Extract(GCWB107) on Decrease of Body Fat
NCT04023864
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism
NCT02366156
The Effect of a Nutritional Supplement Product Containing Cactus Fruit Juice (Nopalea) on C-Reactive Protein
NCT01881178
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
This design allows for the comparison of the effects of different doses or treatments (in this case, different amounts of nopal) against a control (the diet alone).
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I (first arm): 5 g of dehydrated nopal + normocaloric diet.
Supplementation: 5 g of dehydrated nopal (2.47 g of fiber per day), reconstituted in water, taken before breakfast. Diet: 27.53 g of fiber per day, Normocaloric diet: Carbohydrates: 55%, Lipids 25% and Proteins 20%
supplementation with 5 g dehydrated nopal powder from highly mature cladodes
Group I received 5 g of dehydrated Opuntia ficus-indica cladodes plus the standard normocaloric diet for dyslipidemia.
Group II (second arm): 15 g of dehydrated nopal + normocaloric diet.
Supplementation: 15 g of dehydrated nopal (7.42 g of fiber per day), reconstituted in water, taken before breakfast and at night. Diet: 22.58 g of fiber per day, Normocaloric diet: Carbohydrates 55%, Lipids 25% and Proteins 20%
supplementation with 15 g dehydrated nopal powder from highly mature cladodes
Group II received 15 g plus the diet, and Group III followed only the diet.
Group III (third arm): normocaloric diet only (control or comparison group).
No dehydrated nopal or placebo. 30 g of fiber per day Normocaloric diet Carbohydrates 55%, Lipids 25% and Proteins 20%
Control Group (only diet)
No dehydrated nopal or placebo. Diet: 30 g of fiber per day Normocaloric diet Carbohydrates 55%, Lipids 25% and Proteins 20%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
supplementation with 5 g dehydrated nopal powder from highly mature cladodes
Group I received 5 g of dehydrated Opuntia ficus-indica cladodes plus the standard normocaloric diet for dyslipidemia.
supplementation with 15 g dehydrated nopal powder from highly mature cladodes
Group II received 15 g plus the diet, and Group III followed only the diet.
Control Group (only diet)
No dehydrated nopal or placebo. Diet: 30 g of fiber per day Normocaloric diet Carbohydrates 55%, Lipids 25% and Proteins 20%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* overweight or obesity
* A cardiovascular risk factor associated with abdominal obesity
Exclusion Criteria
* Diabetes
* Hypertension
* Thyroid disease were excluded from the study
* Patients with complex or severe disease such as heart failure, liver or kidney disease
* Pregnant or lactating women
* Indidividuals taking lipid-modifying drugs or hormone replacement therapy - Patients with gastrointestinal problems and deficiencies
20 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Autónoma de Querétaro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maria de los Angeles Aguilera Barreiro
Director and Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Autonomous University of Queretaro
Juriquilla, Querétaro, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FCN-10310
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.